Replies to post #488919 on Anavex Life Sciences Corp (AVXL)

[sab63090]

Investor:
1) No rigid regulatory requirement based on size of trial and duration
2) No requirement for ADL to be used as a primary endpoint in an early AD trial

I assume you don't agree?